Homozygosity for SCN4A Arg1142Gln causes congenital myopathy with variable disease expression

Sloth, Christine K; Denti, Federico; Schmitt, Nicole; Bentzen, Bo Hjorth; Fagerberg, Christina; Vissing, John; Gaist, David

Published in:
Neurology: Genetics

DOI:
10.1212/NXG.0000000000000267

Publication date:
2018

Document version
Final published version

Document license
CC BY-NC-ND

Citation for published version (APA):

Terms of use
This work is brought to you by the University of Southern Denmark through the SDU Research Portal. Unless otherwise specified it has been shared according to the terms for self-archiving. If no other license is stated, these terms apply:

• You may download this work for personal use only.
• You may not further distribute the material or use it for any profit-making activity or commercial gain
• You may freely distribute the URL identifying this open access version

If you believe that this document breaches copyright please contact us providing details and we will investigate your claim. Please direct all enquiries to puresupport@bib.sdu.dk
Homozygosity for SCN4A Arg1142Gln causes congenital myopathy with variable disease expression

Christine K. Sloth, MD, Federico Denti, PhD, Nicole Schmitt, PhD, Bo Hjorth Bentzen, PhD, Christina Fagerberg, MD, John Vissing, DMSci, and David Gaist, PhD

Neurol Genet 2018;4:e267. doi:10.1212/NXG.0000000000000267

Congenital myopathy has recently been associated with biallelic pathogenic variants in the SCN4A gene that encodes the voltage-dependent sodium channel NaV1.4.1,2 In 13 previously reported cases,1,2 7 died in utero or shortly after birth. The 6 survivors showed features consistent with “classical” congenital myopathy. Here, we report 2 new familial cases with variable phenotype.

Written informed consent was obtained from both patients. Permission for the study was granted by the Danish Data Protection Agency.

The index patient, an 18-year-old woman, born as the second of 2 children to consanguineous parents, reported weakness and dyspnea from early childhood. Pregnancy and birth were normal, but postpartum, she had dysphagia and was tube fed. Early motor milestones were delayed, with independent ambulation achieved at age 2.25 years and inability to lift her head from a supine position until age 3 years. She experienced improvement in her condition throughout childhood, but still had reduced walking distance (2.5 km), difficulty lifting heavy objects, and experienced patella luxations.

On examination, the patient is 150 cm tall and has a dolichocephalic head shape and elbow hypermobility (figure 1A). Strength testing showed diffuse muscle force reduction at Medical Research Council (MRC) grade 4, with no distal/proximal gradient, and axial weakness. Spirometry showed normal forced vital capacity (FVC) (88%) and forced expiratory volume (FEV1) (96%).

Creatine kinase (CK) levels and neurophysiologic findings were normal. Replacement of muscle by fat on MRI was pronounced in gluteus maximus and hamstring muscles (figure 1B). Muscle biopsy, at age 4 years, displayed myopathic features with varying fiber size, increased number of internalized nuclei, atrophic fibers, and endomysial fibrosis and fat infiltration.

Next-generation sequencing revealed homozygosity for a previously described missense variant in SCN4A (NM_000334.4: c.3425G>A(p.Arg.1142Gln)),2 confirmed through Sanger sequencing, and was deemed to be pathogenic by 6 prediction tools. Parents were heterozygous for the variant.

The 22-year-old sister of the index patient was also homozygous for Arg1142Gln. She had milder muscular complaints than her sister, which included difficulties lifting her head when lying down, exertional shortness of breath, and poor cycling capacity since childhood. She had elbow joint hypermobility like her sister. Her motor milestones were normal. Strength testing...
Figure 1 Clinical features in sisters with SCN4A congenital myopathy

Featuring the dococephalic head form in the index patient (left image) and hypermobility of the elbows in both sisters (middle and right image) (A). T1-weighted muscle MRI images of the index patient show severe fatty infiltration and atrophy of gluteus medius (arrows, left image) and adductor magnus and, to a lesser degree, the hamstrings bilaterally (right image) (B).

Figure 2 The mutation R1142Q causes loss-of-function of Na\textsubscript{v}1.4 current

(A) Representative current traces for Na\textsubscript{v}1.4 WT and R1142Q recorded from transiently transfected HEK293 cells. (B) I\textsubscript{V} relationship for the peak current density for Na\textsubscript{v}1.4 WT (n = 9) and R1142Q (n = 8). Voltage protocol shown as inset. (C) Steady-state inactivation and activation curves for Na\textsubscript{v}1.4 WT (black) and R1142Q (gray). Voltage protocol shown as inset. (D) Comparison of activation V\textsubscript{50} values between Na\textsubscript{v}1.4 WT (black) and R1142Q (gray). *p < 0.05; **p < 0.006; ***p < 0.0001.
showed reduced neck flexion (MRC 4+), shoulder abduction (MRC+4), and hip flexion (MRC 4+). CK, lung function tests, and MRI of thigh muscles were normal.

Functional assessment of the Arg1142Gln (R1142Q) variant in human embryonic kidney 293 (HEK293) cells revealed partial loss-of-function effects (figure 2), as previously reported in SCN4A-related congenital myopathy.1,2 Na+1.4 R1142Q peak current density was significantly lower than wild type (WT) (WT: 106.4 ± 12.4 pA/pF, R1142Q: −39.0 ± 6.4 pA/pF at 5 mV, figure 2, A and B), and the voltage dependence of channel activation was significantly changed (figure 2, C and D).

Variants in SCN4A were originally linked to congenital myasthenia,3,4 but recently, also to severe fetal hypokinesia and early lethality5 and to sudden infant death syndrome.6 A strikingly milder phenotype of “classical” congenital myopathy has been described in 6 patients with SCN4A variants in a recessive pattern, only 3 of whom were adults (aged 18–35 years old).1,2 Our 18-year-old index patient exhibited a phenotype similar to that previously reported,1 while her 20-year-old sister was only marginally affected. Our index patient’s characteristic muscle MRI findings were similar to 4 other patients with SCN4A mutations, including 2 brothers, compound heterozygous for c.3425G>A(p.Arg1142Gln) and another missense variant c.1123T>C (p.Cys375Arg).1,2 The brothers, unlike our patients, had elongated faces, ptosis, facial weakness, scoliosis, and elevated CK.2 We speculate whether homozygosity for the p.Arg1142Gln variant conferred the milder phenotype observed in our patients. The present report expands our knowledge regarding SCN4A-related congenital myopathy in adulthood and underscores that the phenotype of this disorder may vary considerably, even within members of the same family, as in other recessive channelopathies affecting muscles.6

Author contributions
C.K. Sloth: drafted the manuscript and performed administrative work. F. Denti: tested the effect of the SCN4A mutation in a cell line. N. Schmitt: tested the effect of the SCN4A mutation in a cell line, interpreted data, revised the manuscript, and drafted figures. B.H. Bentzen: tested the effect of the SCN4A mutation in a cell line. C. Fagerberg: in charge of DNA-testing of the 2 sisters and revised the manuscript.

J. Vissing and D. Gaist: design, revised the manuscript, interpreted clinical data, and drafted figures.

Study funding
This study did not receive external funding.

Disclosure
C.K. Sloth, F. Denti, N. Schmitt, B.H. Bentzen, and C. Fagerberg report no disclosures. J. Vissing has served on the scientific advisory boards of Sanofi Genzyme, aTyr Pharma, Ultradynex Pharmaceuticals, Santhera Pharmaceuticals, Sarepta Therapeutics, Audentes Therapeutics, Novo Nordisk, Alexion Pharmaceuticals, and Stealth BT; has received travel funding and speaker honoraria from Sanofi Genzyme, Ultradynex Pharmaceuticals, Santhera Pharmaceuticals, and aTyr Pharma; serves on the editorial boards of Neuromuscular Disorders and the Journal of Neuromuscular Diseases; has been a consultant for Sanofi Genzyme, Ultradynex Pharmaceuticals, Santhera Pharmaceuticals, and aTyr Pharma; and has received research support from the Danish Medical Research Council, the University of Copenhagen, the Augustinus Foundation, the NOVO Nordic Foundation, and the Lundbeck Foundation. D. Gaist has received honoraria from AstraZeneca (Sweden) for participation as a coinvestigator in a research project and has received research support from the Danish Cancer Society. Full disclosure form information provided by the authors is available with the full text of this article at Neurology.org/NG.

Received June 26, 2018. Accepted in final form July 26, 2018.

References
Homozygosity for SCN4A Arg1142Gln causes congenital myopathy with variable disease expression
Christine K. Sloth, Federico Denti, Nicole Schmitt, et al.
Neurol Genet 2018;4;
DOI 10.1212/NXG.0000000000000267

This information is current as of September 19, 2018

Updated Information & Services
including high resolution figures, can be found at:
http://ng.neurology.org/content/4/5/e267.full.html

References
This article cites 5 articles, 1 of which you can access for free at:
http://ng.neurology.org/content/4/5/e267.full.html#ref-list-1

Subspecialty Collections
This article, along with others on similar topics, appears in the following collection(s):
Ion channel gene defects
http://ng.neurology.org/cgi/collection/ion_channel_gene_defects
Muscle disease
http://ng.neurology.org/cgi/collection/muscle_disease

Permissions & Licensing
Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at:
http://ng.neurology.org/misc/about.xhtml#permissions

Reprints
Information about ordering reprints can be found online:
http://ng.neurology.org/misc/addir.xhtml#reprintsus